Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma (INDIGO)

• ClinicalTrials.gov Identifier: NCT04644432
• Recruitment Status: Recruiting
• First Posted: November 25, 2020
• Last Update Posted: November 25, 2020
• Sponsor: Herlev and Gentofte Hospital
• Information provided by (Responsible Party): Ida Rasmussen, Herlev and Gentofte Hospital

Study Description

Brief Summary:

The purpose of the open-label INDIGO-study is to examine whether a first line individualized treatment strategy based on DNA and RNA analyses from the patient's tumor is feasible. Moreover, to involve the patient further in their treatment via patient-reported outcomes (PRO) measurements in a value-based healthcare setup with simultaneous analyses of the financial costs of this strategy.

The patients are assigned into 4 treatment arms according to the results of their DNA and RNA analyses. All patients receive electronic questionnaires regarding symptoms and side effects weekly and questionnaires regarding quality of life monthly. Based on each patient's answers of the questionnaires the patient receives advices in the app to reduce the symptoms and side effects or the patient is instructed to contact the hospital.

The hypothesis: Basing the choice of first-line treatment for DNA mutations and RNA profiles in a heterogeneous patient population increases the overall response rate for the total population to 30% compared to 10% for historical cohorts.

Condition or disease	Intervention/treatment	Phase
Metastatic Renal Cell Carcinoma; Kidney Neoplasm; Urologic Neoplasms; Urogenital Neoplasms	Drug: Medication (A specification is listed under each arm); Other: Patient reported outcomes measurement	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 30 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Study of an Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
• Actual Study Start Date: March 6, 2020
• Estimated Primary Completion Date: September 6, 2022
• Estimated Study Completion Date: September 6, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: A - for patients with a DNA mutation that match a targeted treatment; Listed below are the possible study drugs and dosages: Erlotinib 150 mg once a day for 4 weeks. Osimertinib 80 mg once a day for 4 weeks. Alectinib 600 mg twice a day for 4 weeks Dabrafenib 150 mg twice a day combined with Trametinib 2 mg once a day for 4 weeks Trastuzumab-emtansin iv infusion 3.6 mg/kg every 3rd week Olaparib 400 mg twice a day for 4 weeks Pembrolizumab iv infusion 2 mg/kg every 3rd week Cabozantinib 60 mg once a day for 4 weeks Crizotinib 250 mg twice a day for 4 weeks Palbociclib 125 mg once a day in3 weeks, hereafter pause for one week Imatinib 400 mg once a day for 4 weeks If the patient can fit in several arms, arm A or the arm closest to arm A is chosen.	Drug: Medication (A specification is listed under each arm); Study drugs and dosages are listed in the description of arms.; Other: Patient reported outcomes measurement; PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events. The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital. For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.; Other Name: PRO
Experimental: B - for patients with an angiogen profile; Study drug: Sunitinib peroral tablet 50 mg once a day for 4 weeks, hereafter pause for 2 weeks (4/2 schedule or 2/1 schedule). If the patient can fit in several arms, arm A or the arm closest to arm A is chosen.	Drug: Medication (A specification is listed under each arm); Study drugs and dosages are listed in the description of arms.; Other: Patient reported outcomes measurement; PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events. The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital. For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.; Other Name: PRO
Experimental: C - for patients with an immune profile; Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week. If the patient can fit in several arms, arm A or the arm closest to arm A is chosen.	Drug: Medication (A specification is listed under each arm); Study drugs and dosages are listed in the description of arms.; Other: Patient reported outcomes measurement; PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events. The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital. For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.; Other Name: PRO
Experimental: D - for patients that have neither mutations nor an immune- or angiogen profile; Study drug: Nivolumab iv infusion 6 mg/kg (max 480 mg) every 4th week. If the patient can fit in several arms, arm A or the arm closest to arm A is chosen.	Drug: Medication (A specification is listed under each arm); Study drugs and dosages are listed in the description of arms.; Other: Patient reported outcomes measurement; PRO questionnaires regarding symptoms and side effects with questions selected from the Nation Cancer Institute Patient Reported Outcomes-Common Terminology Criteria for Adverse Events. The patient receive individual advices according to the patient's answers to reduce the symptoms and side effects or is instructed to contact the hospital. For monitoring quality of life the EORTC QLQ-C30 is used. All questionnaires are in Danish.; Other Name: PRO

Outcome Measures

Primary Outcome Measures :

1. Overall response rate (ORR) [ Time Frame: 30 months ]
   The total share of patients who have received treatment with complete and partial response assessed radiologically based on RECIST v.1.1.
2. Time to treatment failure (TTF) [ Time Frame: 30 months ]
   The time from start up day 1 until discontinuation of treatment, regardless of the reason.

Secondary Outcome Measures :

1. Overall Survival (OS) [ Time Frame: 30 months ]
   Overall survival for the total population
2. Progression-Free Survival (PFS) [ Time Frame: 30 months ]
   Progression-free survival for the total population
3. Disease Control Rate (DCR) [ Time Frame: 30 months ]
   Disease control rate (complete response + partial response + stabile disease) for the total population based on RECIST v1.1 criteria
4. Response duration [ Time Frame: 30 months ]
   Response duration for the total population.
5. Use of PRO tools [ Time Frame: 30 months ]
   The patients' use of PRO tools during treatment assessed with the validated Patient Feedback Form
6. PRO and PRO-CTCAE [ Time Frame: 30 months ]
   Number of and changes in Patient-reported outcomes according to PRO-CTCAE from baseline.
7. NCI-CTCAE [ Time Frame: 30 months ]
   Number of and types of adverse events according to NCI-CTCAE
8. Hospital admissions [ Time Frame: 30 months ]
   Number of hospital admissions

Other Outcome Measures:

1. Quality of life questionnaires EORTC QLQ-C30 (general quality of life questionnaire) [ Time Frame: 36 months ]
   Changes in quality of life measured with EORTC-C30 every 4th week during treatment

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Signed informed consent form must be obtained before any study-related procedures start.
2. The patient must be willing and able to follow the protocol.
3. Age ≥ 18 years

4. Histological biopsy-confirmed inoperable, locally advanced or metastatic non-cc RCC or 100% sarcomatoid tumour arising from the kidney found unsuited for surgery with a curative intent. Nephrectomy is not mandatory.

   1. If the primary disease was diagnosed more than 1 year ago, a fresh medium needle biopsy must be collected to confirm the diagnosis and tissue must be collected for DNA and RNA analyses.
   2. If a patient with inoperable relapse had a nephrectomy less than 1 year ago, and no tissue samples are stored in Dansk CancerBiobank, a fresh medium needle biopsy must be collected for DNA and RNA analyses.
   3. In cases where metastatic disease was confirmed by biopsy more than 1 year ago without initiated treatment, the patient is offered a fresh medium needle biopsy, but this is not mandatory for inclusion.
   4. If the patient had a nephrectomy using tissue from Dansk CancerBiobank and has been diagnosed with metastases within 1 year, the patient must be offered a fresh medium needle biopsy from a metastasis if the metastasis is easily accessible for biopsy, but a fresh biopsy is not mandatory for inclusion.
   5. A medium needle biopsy is mainly taken from a metastasis, but biopsy from a renal tumour is allowed.
   6. A biopsy may not be taken from bones as it cannot be used for molecular analysis.
   7. If the primary tumour is a proven clear cell RCC, but the biopsy from a metastasis shows non-cc RCC, the patient can be included in the study.
5. Sufficient tissue for DNA analyses, corresponding to 10 slides and RNA analyses corresponding to 1000 tumour cells.
6. Females with a negative pregnancy test or of non-childbearing potential (menopausal, hysterectomy or ovariectomy) and non-breastfeeding.
7. Females of childbearing potential (<2 years after last menstrual period) and males must use effective contraception (pills, intrauterine device, diaphragm or condom with spermicide or sterilisation).
8. Measurable disease (according to RECIST 1.1 criteria)
9. Karnofsky Performance status ≥ 70% / ECOG Performance status 0-2.
10. Life expectancy more than 3 months.
11. At baseline, the laboratory values must be: Haematology: Leukocytes ≥ 3.0 x 109/l, thrombocytes ≥ 100 x 109/l, haemoglobin ≥ 6.2 mmol/l.
12. Biochemistry: International Normalized Ratio (INR) ≤ 1.5, APTT ≤ 1.5 x upper limit of normal (ULN) Total bilirubin ≤ 1.5 x ULN, aspartate transaminase, alanine aminotransferase ≤ 2.5 x ULN for patients without liver metastases, ≤ 5 x ULN for patients with liver metastases. Estimated glomerular filtration rate (eGFR) > 30.

Exclusion Criteria:

1. Previous systemic treatment for metastatic RCC (including neoadjuvant treatment).
2. Former adjuvant treatment with immune checkpoint inhibitors.
3. Major surgical procedure, open surgical biopsy or significant trauma within 28 days prior to initiation.
4. Serious non-healing wound, ulcer or bone fracture.
5. Auto-immune disease or other condition requiring systemic treatment with either corticosteroids (prednisolone > 10 mg/day or similar) or other immunosuppressive drugs
6. Metastases in the central nervous system (CNS). The patient must have an MRI scan (preferred) or CT scan of the brain (using contrast agent if possible) within 28 prior to initiation.
7. Seizures which cannot be managed with standard medical treatment.
8. If urine dipstick with protein ≥ 3+, urine must be collected over a period of 24 hours which must be < 3.5 grams/day. If degree 2 proteinuria, urine must be collected over a period of 24 hours prior to each prescription.
9. Other malignancy within 5 years (except for curatively treated basal cell carcinoma of the skin and/or cervix carcinoma in situ).
10. Uncontrolled hypertension (≥ 150 mm Hg systolic and/or ≥ 100 mm Hg diastolic) despite maximum antihypertensive medical treatment.
11. Clinically significant (i.e. active) cardiovascular disease, such as cerebrovascular conditions (≤ 6 months), myocardial infarction (≤ 6 months), unstable angina, New York Heart Association (NYHA) congestive heart failure ≥ degree III or serious cardiac arrhythmia requiring medical treatment. Patients with well-managed Atrial fibrillation/ atrial flutter may be included.
12. Treatment using other investigational drugs or participation in other studies.
13. Previous or current other diseases, metabolic dysfunction, clinical findings on physical examination or clinical laboratory findings that give suspicion of a disease or condition that would contraindicate the use of an investigational drug or a patient with a high risk of treatment complications.
14. Patients where the investigator finds that patient compliance prevents safe completion of the treatment.

Contacts and Locations

Contacts

Contact: Anne Kirstine H Moeller, MD, PhD; +4538681083; anne.kirstine.hundahl.moeller@regionh.dk

Contact: Jesper A Palshof, MD, PhD; +4538686161; jesper.andreas.palshof@regionh.dk

Locations

Denmark

Department of Oncology, Herlev and Gentofte Hospital; Recruiting

Herlev, Denmark, 2730

Contact: Anne Kirstine H Moeller, MD, PhD +4538681083 anne.kirstine.hundahl.moeller@regionh.dk

Contact: Jesper A Palshof, MD, PhD +4538686161 jesper.andreas.palshof@regionh.dk

Sponsors and Collaborators

Herlev and Gentofte Hospital

Investigators

• Principal Investigator: Ida Marie L Rasmussen, MD; Department of Oncology, Herlev and Gentofte Hospital

More Information

• Responsible Party: Ida Rasmussen, Principal investigator, MD, Herlev and Gentofte Hospital
• ClinicalTrials.gov Identifier: NCT04644432
• Other Study ID Numbers: UR1909; 2019-001316-38 ( EudraCT Number ); PACTIUS ( Other Identifier: P-2019-232 ); GCP ( Other Identifier: 2019-1153 )
• First Posted: November 25, 2020
• Last Update Posted: November 25, 2020
• Last Verified: November 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Ida Rasmussen, Herlev and Gentofte Hospital:

non-clear cell renal cell carcinoma; liquid biopsy; patient reported outcomes; gene expression

Additional relevant MeSH terms:

Carcinoma; Neoplasms; Carcinoma, Renal Cell; Kidney Neoplasms; Urogenital Neoplasms; Urologic Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Adenocarcinoma; Neoplasms by Site; Kidney Diseases; Urologic Diseases